Product category:
Contract research
News Release from: Asinex
Edited by the Laboratorytalk Editorial
Team on 13 July 2005
Milestone reached in drug discovery deal
Asinex has achieved screening results which have met the set criteria of Biovitrum for an undisclosed GPCR target
Asinex announces the triggering of its first milestone payment as a part of a drug discovery collaboration with Biovitrum, a European biotech company focusing on metabolic diseases R and D Asinex has achieved screening results which have met the set criteria of Biovitrum for an undisclosed GPCR target
This article was originally published on Laboratorytalk on 5 Feb 2004 at 8.00am (UK)
Related stories
Successful bioscreening project
Proteom, an in silico molecular design company, and Asinex, a company involved in lead generation and optimisation, have announced the completion of a successful bioscreening project
Biovitrum initially transferred one of its screening assays to Asinex's bioscreening department, which was able to establish the assay at its laboratory in Moscow.
Asinex's computational department performed virtual screening of the in-stock database of more than 400,000 compounds and selected compounds for in-vitro screening, hit compounds were screened in functional assays.
"We believe this is a real step forward for Asinex's bioscreening services.
"It also shows the capabilities we have as a provider of integrated services, having access to our high quality chemical libraries in combination with complementary services.
"The next step for us will be the expansion of our screening services into the area of early Admet screening", said Dmitry Genis, Asinex's CEO.
"We are very pleased that our collaboration with Biovitrum has shown signs of early promise".
• Asinex: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
